DK1028738T3 - Anvendelse af cytokiner og mitogener til at inhibere patologiske immunresponser - Google Patents

Anvendelse af cytokiner og mitogener til at inhibere patologiske immunresponser

Info

Publication number
DK1028738T3
DK1028738T3 DK98957605T DK98957605T DK1028738T3 DK 1028738 T3 DK1028738 T3 DK 1028738T3 DK 98957605 T DK98957605 T DK 98957605T DK 98957605 T DK98957605 T DK 98957605T DK 1028738 T3 DK1028738 T3 DK 1028738T3
Authority
DK
Denmark
Prior art keywords
mitogens
cytokines
immune responses
pathological immune
inhibit pathological
Prior art date
Application number
DK98957605T
Other languages
English (en)
Inventor
David A Uty Of Souther Horwitz
Original Assignee
Univ Southern California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Southern California filed Critical Univ Southern California
Application granted granted Critical
Publication of DK1028738T3 publication Critical patent/DK1028738T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/15—Transforming growth factor beta (TGF-β)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK98957605T 1997-11-05 1998-11-05 Anvendelse af cytokiner og mitogener til at inhibere patologiske immunresponser DK1028738T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6450797P 1997-11-05 1997-11-05
PCT/US1998/023584 WO1999025366A1 (en) 1997-11-05 1998-11-05 Use of cytokines and mitogens to inhibit pathological immune responses

Publications (1)

Publication Number Publication Date
DK1028738T3 true DK1028738T3 (da) 2003-08-11

Family

ID=22056456

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98957605T DK1028738T3 (da) 1997-11-05 1998-11-05 Anvendelse af cytokiner og mitogener til at inhibere patologiske immunresponser

Country Status (11)

Country Link
US (1) US6228359B1 (da)
EP (1) EP1028738B1 (da)
JP (1) JP4309047B2 (da)
AT (1) ATE238061T1 (da)
AU (1) AU747767B2 (da)
CA (1) CA2309115C (da)
DE (1) DE69813868T2 (da)
DK (1) DK1028738T3 (da)
ES (1) ES2198774T3 (da)
PT (1) PT1028738E (da)
WO (1) WO1999025366A1 (da)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6358506B1 (en) 1997-11-05 2002-03-19 University Of Southern California Use of cytokines and mitogens to inhibit pathological immune responses
US20030157057A1 (en) * 1999-05-05 2003-08-21 Horwitz David A. Methods for the induction of professional and cytokine-producing regulatory T cells
US6803036B1 (en) 1998-03-03 2004-10-12 University Of Southern California Use of cytokines, cells and mitogens to inhibit graft versus host disease
AU3066599A (en) 1998-03-03 1999-10-18 University Of Southern California Use of cytokines and mitogens to inhibit graft versus host disease
AU771080B2 (en) * 1999-05-05 2004-03-11 University Of Southern California Use of cytokines and mitogens to inhibit pathological immune responses
DE60042210D1 (de) * 1999-09-01 2009-06-25 Univ Southern California Verwendung von cytokinen, zellen und mitogene zur hemmung der graft-versus-host krankheit
AU2007202534B2 (en) * 2000-04-11 2011-06-09 University Of Southern California A method to prevent graft rejection using TGF-beta to induce T suppressor cells
AU5340001A (en) * 2000-04-11 2001-10-23 Univ Southern California A method to prevent graft rejection using tgf-beta to induce t suppressor cells
JP2005514054A (ja) * 2001-12-21 2005-05-19 ユニバーシティ・オブ・サザン・カリフォルニア プロフェッショナルおよびサイトカイン産生制御t細胞の誘導のための方法
US20050202010A1 (en) * 2003-08-29 2005-09-15 Giroir Brett P. Method of treatment and bioassay involving macrophage migration inhibitory factor (MIF) as cardiac-derived myocardial depressant factor
US8951796B2 (en) 2010-04-22 2015-02-10 University Of Southern California Methods and compositions for expanding and stabilizing natural regulatory T cells
WO2013050529A2 (en) 2011-10-06 2013-04-11 European Molecular Biology Laboratory Use of igf-1 in the modulation of treg cell activity and the treatment and prevention of autoimmune disorders or diseases
AU2012320597C1 (en) 2011-10-07 2015-10-15 Baxalta GmbH oxMIF as a diagnostic marker
US20150110738A1 (en) 2012-05-04 2015-04-23 University Of Southern California Methods and compositions for generating and using allogeneic suppressor cells
GB201421716D0 (en) * 2014-12-05 2015-01-21 King S College London Cell expansion procedure

Also Published As

Publication number Publication date
JP4309047B2 (ja) 2009-08-05
ES2198774T3 (es) 2004-02-01
DE69813868D1 (de) 2003-05-28
US6228359B1 (en) 2001-05-08
JP2001523443A (ja) 2001-11-27
AU1382799A (en) 1999-06-07
ATE238061T1 (de) 2003-05-15
AU747767B2 (en) 2002-05-23
CA2309115A1 (en) 1999-05-27
WO1999025366A1 (en) 1999-05-27
EP1028738A1 (en) 2000-08-23
EP1028738B1 (en) 2003-04-23
CA2309115C (en) 2010-10-19
DE69813868T2 (de) 2004-03-04
PT1028738E (pt) 2003-08-29

Similar Documents

Publication Publication Date Title
ATE238061T1 (de) Verwendung von zytokinen und mitogenen für inhibierung von pathologischen immunantworten
DK442788D0 (da) Fremgangsmaade og praeparat til behandling af non-ige-medierede lidelser
PL374865A1 (en) Treatment of tnf alpha related disorders
AR243600A1 (es) Un aparato para el tratamiento de muestras biologicas y microbiologicas.
EA199900349A1 (ru) Каталитическая субъединица теломеразы человека
NZ294446A (en) Stem cell proliferation inhibitors, haemoglobin chains used for the treatment of autoimmune diseases.
DE69725153D1 (de) Kaliumkanal-blocker
NO20001583D0 (no) Stimulering av hematopoetiske celler in vitro
TR199802676A2 (xx) T�m�rlerin, t�m�rle ilgili hastal�klar�n ve ka�eksinin tedavisi ve �nlenmesi i�in y�ntem.
NO971902L (no) Bindingsmidler til CD23
IT8224081A0 (it) Procedimento, dispositivo e disposizione di regolazione per trattare rottame di metallo duro mediante alligatura.
FR2491334B1 (da)
EP0414019A3 (en) Subsituted n-(quinolin-2-yl-methoxy)benzylsulfonylureas
ATE53302T1 (de) Mittel zur behandlung von wunden.
ES2128348T3 (es) Obtencion de composiciones para el tratamiento de alteraciones de la proliferacion celular.
BG101126A (en) The use of muramylpeptide compounds
Rachman Psychotherapy of difficult cases: Flexibility and responsiveness in contemporary practice.
DK1173549T3 (da) Anvendelse af cytokiner og mitogener til inhibering af pathologisk immun-responser
IT7824108A0 (it) Dispositivo e procedimento per il trattamento di acque di scarico contenenti metalli pesanti.
FI831059A7 (fi) Menetelmä ja laite akvaarioveden biologiseksi, anaerobiseksi typen poistamiseksi.
EP1291020A3 (en) Use of cytokines and mitogens to inhibit pathological immune responses
EP0116628A4 (en) 1-ACYL-3-PYRIDYLMETHYLGUANIDINE AND THEIR USE AS AN ANI-HYPERTENSIVE.
DE69012883D1 (de) Methode für die Behandlung von Abgas.
DK410087A (da) Lavviskoese sulfurerede alkylphenoler, overbaserede med gruppe ii metaller
PT85658A (pt) Aparelhagem para o tratamento de plantas de latada em estufas de bloco